FCMV
OKUR

Foresite Capital Management VI’s OnKure Therapeutics OKUR Stock Holding History

Foresite Capital Management VI’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,445,783
Closed -$5.99M – 25
2026
Q1 		$5.99M Buy
+1,445,783
New +$4.46M 1.3% 14

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Foresite Capital Management VI's OKUR Position: Q2 2026 in Review

Foresite Capital Management VI sold out of OnKure Therapeutics (OKUR) in Q2 2026, closing a stake of 1,445,783 shares — an estimated $5.99M sold.

Foresite Capital Management VI first reported a position in OKUR in Q1 2026 and held it in 1 quarter. The position peaked at $5.99M in Q1 2026. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Foresite Capital Management VI reported no remaining OnKure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Foresite Capital Management VI sold 1,445,783 OnKure Therapeutics shares in Q2 2026, an estimated $5.99M.
  • Foresite Capital Management VI first reported a position in OnKure Therapeutics in Q1 2026 and held it in 1 quarter.
  • Foresite Capital Management VI's OnKure Therapeutics position peaked at $5.99M in Q1 2026.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Foresite Capital Management VI's 13F filing for Q2 2026, filed 14 Aug 2026.